Drug Profile

CSB 001

Alternative Names: CSB-001

Latest Information Update: 09 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Claris Biotherapeutics
Class Anti-inflammatories; Antifibrotics; Eye disorder therapies; Growth factors; Recombinant proteins
Mechanism of Action Hepatocyte growth factor replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

04 Jun 2024 Claris Biotherapeutics completes phase-I/II trial in Neurotrophic keratopathy in USA and Canada (Ophthalmic) (NCT04909450)
15 May 2024 Phase-I clinical trials in Limbal stem cell deficiency in USA (Ophthalmic) (NCT06452316)
05 Feb 2024 Phase-I clinical trials in Corneal injuries in USA (Ophthalmic) (NCT06257355)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com